Dual-responsive nanodelivery system enhances immunotherapy efficacy in metastatic bladder cancer
Metastatic urothelial carcinoma has a poor prognosis: ~50% of muscle-invasive bladder cancer progresses to metastasis, and the 5-year survival for advanced/metastatic disease is <10%.